Skip to content
My WebMD Sign In, Sign Up

Multiple Sclerosis Health Center

Font Size
A
A
A

Tysabri Therapy for Multiple Sclerosis

Tysabri is approved as single therapy for the treatment of people with relapsing forms of multiple sclerosis (MS) to reduce the frequency of flare-ups and delay progression of physical disability.

After the FDA initially approved Tysabri, the drug's manufacturer took the drug off the U.S. market due to reports of a rare, but serious brain infection called PML (progressive multifocal leukoencephalopathy). But the drug returned to the market after the drugmaker included a risk-minimization program with mandatory patient registration and periodic follow-up to identify any possible cases of PML as soon as possible.

Recommended Related to Multiple Sclerosis

How MS Disability Is Measured

Multiple sclerosis (MS) is a complex disease. Multiple sclerosis progression varies from person to person. And, the various MS types of disease progress in different ways, too. Scans and other multiple sclerosis tests don't always tell the whole story about MS disability. Signs and symptoms and how well you are functioning each day -- from seeing to moving to thinking -- are also important measures of how well your central nervous system is working. That's why a variety of tools are useful in assessing...

Read the How MS Disability Is Measured article > >

The risk for PML increases with the number of doses received. Data that's been collected by the FDA indicates the risk is 0.3 per 1,000 patients treated for up to 24 months, 1.5 per 1,000 patients treated for 25-26 months, and 0.9 per 1,000 patients treated for 37-48 months.

Risk also is higher among patients treated with immune-suppressing therapy before using Tysabri. Because of this risk, Tysabri is usually recommended for patients who cannot tolerate or have not responded to other MS treatments.

Tysabri is unique among MS drugs in that it works by binding to a protein found on the surface of immune cells (white blood cells), which are believed to play a role in the damaging effects of MS. Tysabri, a monoclonal antibody, curbs the ability of white blood cells to enter the brain and spinal cord.

Who Should Receive Tysabri for Multiple Sclerosis

Tysabri can be prescribed to treat patients who have relapsing forms of multiple sclerosis. The drug reduces the frequency of MS attacks and delays worsening of physical disability.

How Is Tysabri Given for Multiple Sclerosis?

Tysabri is given to those with multiple sclerosis intravenously (through a vein) over the course of an hour every four weeks in a doctor's office.

What Are the Side Effects of Tysabri?

The most common side effects are:

  • infections
  • headache
  • fatigue
  • depression
  • joint pain
  • menstrual problems

It is important that patients are observed for one hour after each infusion in case an allergic reaction develops. Symptoms of allergic reactions include hives, itching, breathing problems, chest pain, nausea, flushing, dizziness, and rash.

Besides PML and allergic reactions, other serious side effects include liver damage and serious infections.

As is the case with all medications, it is important to weigh the risks and benefits carefully. Talk to your doctor to determine if this treatment is right for you.

WebMD Medical Reference

Reviewed by Neil Lava, MD on June 26, 2013

Today on WebMD

MS Overview
Slideshow
Woman sitting with arms on knees
Video
 
When MS Attacks
Article
Vials of pills
Video
 
Doctor and patient
Article
MS and Exercise
Article
 
Syringe
Article
MS Hormone
Article
 
Taking Control Sleep
Article
MS brain scan
Slideshow
 
Recognizing MS
Article
MS Causes
Article